Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Behaviour: deterioration of behaviour (categorised as reason to leave early) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in leaving the study early ‐ any reason compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
1 finding from 1 review
Leaving the study early · people with severe mental disorders
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with non‐Intensive Case Management (low certainty).
1 finding from 1 review
Leaving the study early · people with severe mental disorders
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with standard care (low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia or related disorders
Combinations of antipsychotic drugs showed no clear difference in leaving the study early compared with single antipsychotic drugs (low certainty).
1 finding from 1 review
Leaving the study early · antipsychotic‐related constipation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · antipsychotic‐related constipation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · antipsychotic‐related constipation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
It is very uncertain whether chlorpromazine changes leaving the study early: for any reason compared with clotiapine (very low certainty).
1 finding from 1 review
Intervention not reported
Leaving the study early: any reason (medium term) · patients with schizophrenia
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
YOGA probably leads to lower leaving the study early: short term compared with NON‐STANDARD CARE (moderate certainty).
1 finding from 1 review
Leaving the study early Leaving the study early: participants lost to · patients with schizophrenia
1 finding from 1 review
Leaving the study early · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
Oral health education (advice and training) showed no clear difference in leaving the study early compared with standard care (oral health advice not specifically emphasised beyond… (moderate certainty).
1 finding from 1 review
Leaving the study early · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
Motivational interview plus oral health education showed no clear difference in leaving the study early compared with oral health education (moderate certainty).
1 finding from 1 review
Leaving the study early · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
Monitoring (any means of observation, supervision, keeping under… showed no clear difference in leaving the study early compared with no monitoring (moderate certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review